17. TARGETED THERAPY / OMALIZUMAB
Pelaia G. J Asthma Allergy. 2011; 4: 49–59.
TTD Astım Tanı ve Tedavi Rehberi.2014.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org
Up To Date
Omalizumab can be used patients
who have below critria:
• In Step 5
• Severe eosinophilic asthma who is
uncontrolled with inhaled
corticosteroids and/or other
therapies
• Sensitive to a perennial allergen
which prove(s) skin prick test and/or
with spesific-IgE
• And total IgE should be between 30
and 1500 I.U./mL
22. ANTI-IL-5(MEPOLIZUMAB)-CONCLUSION
According to GINA
2016 guideline,
mepolizumab can be
used in step 5 whose
asthma is severe
eosinophilic and
uncontrolled but
only older than 12
years patients..
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org
23. In both studies, patients
receiving reslizumab had a
significant reduction in the
frequency of asthma
exacerbations (study 1: rate
ratio [RR] 0.50 [95% CI 0.37–
0.67] ; study 2: 0.41
[0.28–0.59]; both p<0.0001)
compared with those
receiving placebo.
24. Compared with placebo,
benralizumab reduced asthma
exacerbation rates by 49% (3.59 vs
1.82; P=.01) and exacerbations
resulting in hospitalization by 60%
(1.62 vs 0.65; P=.02) in the
combined groups.
25. Both dose of benralizumab can decrease levels of ECP and EDN. For the combined
benralizumab groups, ECP declined from a baseline mean (SD) of 26.1 (30.3) μg/L to 8.6
(9.1) μg/L at day 84, and EDN declined from 25.67 (33.80) ng/mL to 4.79 (9.87) ng/mL.
Visits to the ED at week 24 were lower in the combined benralizumab groups compared
with placebo (weighted rate of 2.95 vs 4.32; P = .02).
28. Treatment with
lebrikizumab
reduced the rate of asthma
exacerbations, which was
more pronounced in the
periostin-high patients
(all doses: 60% reduction)
than in the periostin-low
patients (all doses: 5%
reduction); no dose–
response was evident.
Lung function also improved following lebrikizumab treatment, with
greatest increase in FEV1 in periostin-high patients (all doses: 9.1%
placebo adjusted improvement) compared with periostin-low patients
(all doses: 2.6% placebo-adjusted improvement).
29. In patients in this subgroup
who also had baseline serum
dipeptidyl peptidase-4 (DPP-4)
higher than the population
baseline median, we noted
additional improvements in
prebronchodilator FEV1, ACQ-6,
and AQLQ(S), and, in those with
periostin concentrations higher
than the median, we noted
improvements in asthma
exacerbation rate,
prebronchodilator FEV1, and
ACQ-6.
30. THE PROBLEMS OF THE NEW THERAPEUTICS
Injection site reactions
Nasopharyngitis
Headache
Anaphylaxis(rarely)
31. 30% - %70
Rabe KF, et al. J Allergy Clin Immunol 2004; 114: 40-7.
Sekerel BE, et al. Respir Med 2006; 100: 1850-4.
A phenotype is defined as the composite observable
characteristics or traits of an organism that result
from genetic as well as environmental influences.
For a chronic disease such as asthma, phenotyping
may be useful in providing long-term prediction of
outcomes and determining specific treatments for
selected phenotypes, such that these differences
between individual patients can be exploited to
relate to clinically meaningful outcomes. Cluster
analysis of clinical and physiological features is
increasingly used to define phenotypes of asthma
(Table 1). In the Severe Asthma Research Program
(SARP) and the UK Leicester adult cohorts, hierarchical
cluster analysis of populations with a range
of asthma severities was used [6, 7]. Patient
clusters were either identified with minimal airflow
obstruction and low disease activity, early disease
onset and an atopic background or associated with
adult-onset and active disease (more severe group
of patients with asthma) (Table 1). Thus, age at
disease onset, lung function and atopic state
featured highly in these clusters or phenotypes,
as also observed in cohorts from Korea and Japan
[8, 9]. Clusters related to more severe disease were
represented in the adult SARP cohort by individuals
on high-dose ICS therapy, often combined with
oral corticosteroid treatment associated with
severe airflow obstruction. In the TENOR study, a
cluster described in adolescents and adults was
associated with aspirin sensitivity, in primarily
White, female and atopic patients with late-onset
asthma, and these patients were more likely to
experience exacerbations [10].
The obesity component in severe asthma defined in
both the SARP and Leicester cohorts has also been
described in other analyses [11, 12], with obese
uncontrolled and obese well-controlled clusters
that differed from one another with regard to age
of asthma onset, measures of asthma symptoms
and control, exhaled nitric oxide concentration
(FeNO) and airway hyper-responsiveness but were
similar with regard to measures of lung function,
airway eosinophilia and serum IgE [11]. A cluster of
obese women with late-onset asthma and frequent
symptoms with high healthcare use but with low
sputum eosinophil counts has also been described
[13].
How is asthma severity assessed?
Asthma severity can be assessed retrospectively from the level of treatment (p14) required to control symptoms and exacerbations. Mild asthma is asthma that can be controlled with Step 1 or 2 treatment. Severe asthma is asthma that requires Step 4 or 5 treatment, to maintain symptom control. It may appear similar to asthma that is uncontrolled due to lack of treatment